COMPASS Pathways (CMPS) Projected to Post Quarterly Earnings on Thursday

COMPASS Pathways (NASDAQ:CMPS) will likely be issuing its quarterly earnings data before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.62) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

COMPASS Pathways Trading Down 12.1 %

NASDAQ:CMPS opened at $3.70 on Tuesday. COMPASS Pathways has a 52 week low of $3.16 and a 52 week high of $12.75. The firm has a 50-day moving average price of $4.08 and a two-hundred day moving average price of $5.32. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.91 and a current ratio of 8.91. The firm has a market cap of $253.16 million, a price-to-earnings ratio of -1.68 and a beta of 2.28.

Analyst Upgrades and Downgrades

Several research firms recently commented on CMPS. Royal Bank of Canada reiterated an “outperform” rating and issued a $18.00 price objective on shares of COMPASS Pathways in a research note on Wednesday, January 15th. Maxim Group cut their price target on COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Finally, HC Wainwright lowered their price objective on COMPASS Pathways from $60.00 to $45.00 and set a “buy” rating on the stock in a research note on Thursday, February 13th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $30.60.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.